Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
1(11%)

Phase Distribution

Ph not_applicable
4
44%
Ph phase_3
1
11%
Ph phase_4
1
11%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
1(11.1%)
N/ANon-phased studies
4(44.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (33.3%)
Phase 31 (11.1%)
Phase 41 (11.1%)
N/A4 (44.4%)

Trials by Status

completed889%
terminated111%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_4

HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers

NCT05272735
completedphase_1

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

NCT00000745
completedphase_1

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

NCT00000633
completednot_applicable

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
completednot_applicable

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

NCT00000943
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05272735Phase 4

HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers

Terminated
NCT00000745Phase 1

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Completed
NCT00000633Phase 1

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

Completed
NCT00013871Not Applicable

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

Completed
NCT00000943Not Applicable

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

Completed
NCT00426712Phase 1

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Completed
NCT02055365Not Applicable

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

Completed
NCT00414050Phase 3

A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

Completed
NCT00001119Not Applicable

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9